FINEARTS-HF
A multicenter, randomized, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy and safety of finerenone on morbidity and mortality in participants with heart failure (NYHA II-IV) and left ventricular ejection fraction ≥40% (LVEF≥ 40%)
- Stage
- klaar
- Medicine
- finerenone
- Population
- Hartfalen
- Phase
- III
- First Patient In
- 25 September 2020
- Last Patient In
- 10 January 2023
- Last Patient Last Visit
- 5 June 2024
National Lead
dr. G.C.M. Linssen
Cardioloog
Office Contact
